Value Framework

Although interest in value assessment frameworks is relatively widespread among payers, significant challenges to operationalizing them exist within the U.S. healthcare system. Those challenges--which include existing policies and a lack of standardized definitions--restrict the ability to make favorable contracts.

Although interest in value assessment frameworks is relatively widespread among payers, significant challenges to operationalizing them exist within the U.S. healthcare system. Those challenges--which include existing policies and a lack of standardized definitions--restrict the ability to make favorable contracts.

AMCP supports the use of value frameworks as a resource for determining the value of pharmaceuticals and other health technologies when the Frameworks are based on sound methods using good scientific evidence and economic models.

ICER's analysis of biologics used to treat asthma falls short of adequately addressing factors related to patients' health and quality of life, particularly those with severe, uncontrolled asthma, according to this JMCP article by the Asthma and Allergy Foundation of America's CEO.

Collaboration and transparency in the development of cost-effectiveness models can increase the credibility and relevance of these models for local decision making, according to this JMCP article.

ICER's analysis of biologics used to treat asthma falls short of adequately addressing factors related to patients' health and quality of life, particularly those with severe, uncontrolled asthma, according to this JMCP article by the Asthma and Allergy Foundation of America's CEO.

Collaboration and transparency in the development of cost-effectiveness models can increase the credibility and relevance of these models for local decision making, according to this JMCP article.